---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-126425"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:36:33.585604+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aileron reports positive LTI-03 Phase 1b Cohort 1 IPF data; cash $12.0M

## Summary
- 7 of 8 biomarkers showed positive trend; 3 statistically significant: GAL-7 (p=0.0014), TSLP (p=0.0223), Col-1α1 (p=0.0489).
- LTI-03 well-tolerated with no serious adverse events; solRAGE increased (p=0.1407), indicating type I epithelial cell health.
- Cohort 1: 12 patients (9 active, 3 placebo), inhaled 2.5 mg BID; cohort 2 high-dose results expected Q3 2024.
- Preliminary cash and cash equivalents ~$12.0M as of March 31, 2024, unaudited.

## SEC filing metadata
- accession: 0001193125-24-126425
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524126425/0001193125-24-126425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524126425/d65915d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-126425
- JSON: https://secwatch.observer/filing/0001193125-24-126425.json
- Plain text: https://secwatch.observer/filing/0001193125-24-126425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.